Form 4 for HRMY Harmony Biosciences Holdings, Inc.
Accepted 2026-09-09 17:12:16 ET · period of report 2026-09-04 · accession 0002009762-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-09 17:12 | 2026-09-04+ | HRMY | Budur Kumar | Chief MEDICAL Off | S - Sale+OE | $42.80 | -34.0K | 13.1K | -72% | -$1.45M |
| DM | 2026-09-09 17:12 | 2026-09-08 | HRMY | Budur Kumar | Chief MEDICAL Off | M - OptEx | $30.49 | +23.0K | 36.1K | +175% | +$699.9K |
| DM | 2026-09-09 17:12 | 2026-09-08 | HRMY | Budur Kumar | Chief MEDICAL Off | M - OptEx | $0.00 | -23.0K | 64.2K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-04 | S | D | 5,500 | $41.98 | 18,615 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.32. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-09-08 | S | D | 4,500 | $42.25 | 14,115 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.59 to $42.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-09-08 | S | D | 1,000 | $42.79 | 13,115 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.59 to $43.02. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-09-08 | M | A | 12,200 | $30.69 | 25,315 | D | — | — | |
| 5 | Common | Common Stock | 2026-09-08 | M | A | 10,754 | $30.27 | 36,069 | D | — | — | |
| 6 | Common | Common Stock | 2026-09-08 | S | D | 22,954 | $43.10 | 13,115 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Stock Option | 2026-09-08 | M | D | 12,200 | $0.00 | 30,300 | D | $30.69 · — to 2034-01-24 | 12,200 Common Stock | (F6) The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date |
| 8 | Derivative | Stock Option | 2026-09-08 | M | D | 10,754 | $0.00 | 64,246 | D | $30.27 · — to 2034-05-01 | 10,754 Common Stock | (F7) The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |